Novo makes oral obesity drug partnership with Lexicon worth up to $1B

Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its oral small molecule drug. Under the deal, Lexicon Pharmaceuticals will ...